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Site-speciﬁc transpositionUsing a rapid and reliable system based on Tn7-mediated site-speciﬁc transposition, we have successfully
constructed a recombinant Oka varicella vaccine (vOka) expressing the mumps virus (MuV) fusion protein
(F). The backbone of the vector was our previously reported vOka–BAC (bacterial artiﬁcial chromosome)
genome. We inserted the transposon Tn7 attachment sequence, LacZα–mini-attTn7, into the region between
ORF12 and ORF13 to generate a vOka–BAC–Tn genome. The MuV–F expressing cassette was transposed into
the vOka–BAC genome at the mini-attTn7 transposition site. MuV–F protein was expressed in recombinant
virus, rvOka–F infected cells. In addition, the MuV–F protein was cleaved in the rvOka–F infected cells as in
MuV-infected cells. The growth of rvOka–F was similar to that of the original recombinant vOka without the
F gene. Thus, we show that Tn7-mediated transposition is an efﬁcient method for introducing a foreign gene
expression cassette into the vOka–BAC genome as a live virus vector.nd Vaccinology, Division of
Innovation 7-6-8, Saito-Asagi,
buted equally to this work.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Varicella-zoster virus (VZV) is a human herpesvirus that causes
varicella (chicken pox) and zoster (shingles). Varicella is character-
ized by viremia and skin lesions as a primary infection in children
(Cohen et al., 2007). Herpes zoster is caused by the reactivation of VZV
from sensory ganglia, where VZV establishes latency. The incidence
of herpes zoster increases with age or immunosuppression (Arvin,
1996).
To control VZV infections, a live attenuated varicella vaccine, the
Oka vaccine strain (vOka), was developed from the Oka parental
strain (pOka) (Takahashi et al., 1974). The vOka was attenuated by
multiple passages in human and guinea pig cells, and the resulting
varicella vaccine became the ﬁrst herpesvirus vaccine licensed for use
in humans. This vaccine is efﬁcient and causes few adverse events, and
consequently is the only strain to be used worldwide (Arvin, 2001;
Chaves et al., 2008).
Because this vaccine has been studied for more than 20 years,
its immunogenicity and safety are well documented (Arvin andGreenberg, 2006; Galea et al., 2008; Takahashi et al., 1992), which
provides a distinct advantage in choosing it as a vector over other
attenuated vaccines. In addition, because of the size of its genome, it
can accommodate and maintain large DNA inserts. vOka has been
used as a vector to express the Epstein–Barr virus membrane
glycoprotein (gp350/220) (Lowe et al., 1987), hepatitis B surface
antigen (Shiraki et al., 1991), human immunodeﬁciency virus Env
(Shiraki et al., 2001), and herpes simplex virus type 2 glycoprotein D
(Heineman et al., 1995).
We recently succeeded in cloning the vOka genome into a bacterial
artiﬁcial chromosome (BAC) (Yoshii et al., 2007). This vOka–BAC
system allows the stable maintenance of the vOka genome in E. coli,
and is useful for inserting foreign genes into the vOka genome (Wagner
et al., 2002). Using the vOka–BAC system, we previously constructed a
recombinant vOka containing the mumps virus (MuV) hemagglutinin–
neuraminidase (HN) gene, rvOka–HN (Somboonthum et al., 2007), and
showed that the recombinant vOka is potentially useful as a polyvalent
vaccine providing protection for both VZV and mumps virus infections.
Since the MuV–F protein has also been reported to play an important
role in protection (Hishiyama et al., 1988; Sakata et al., 1984), the role of
the F protein should also be considered.
Previously, we used RecA recombinase to introduce the HN gene
into the vOka–BAC genome (Somboonthum et al., 2007). However, it
takes 4–5 weeks to accomplish this kind of RecA recombinase-
mediated recombination in E. coli, and the method is complicated.
Fig. 1. Construction of the rvOka–F genome. The vOka–BAC genome (A) is about 125-
kbp long and includes terminal repeats (TRL and TRS), a unique long (UL) domain,
internal repeats (IRL and IRS), and a unique short domain (US). Note that the BAC
vector sequence is ﬂanked by Cre–lox recombination sites (loxP). The LacZα–mini-
attTn7 sequence in pKO5M-Tn (B) was inserted between ORF12 and ORF13 of the
vOka–BAC genome by RecA-mediated recombination. RecA was encoded by pDF25
(tet). The LacZα–mini-attTn7 sequence in the vOka–BAC–Tn (C) genome permitted
site-speciﬁc insertion of the MuV–F expression cassette of pFASTBacCMV–MuV–F
plasmid (D) by Tn7-mediated transposition. The BAC sequence was removed from
vOka–BAC–F (E) by Cre-mediated recombination. The resulting bacmid, rvOka–F (F),
was used for reconstitution of the recombinant virus.
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place in the genome. The bacterial transposon Tn7 targets a speciﬁc
site in E. coli genome called attTn7 (Barth et al., 1976; Lichtenstein and
Brenner, 1981), which contains a 68-base-pair DNA segment that is
essential for targeting by Tn7 (McKown et al., 1988). Four Tn7-
encoded genes, tnsABC and tnsD are required for the target site-
speciﬁc transposition of Tn7 (Kubo and Craig, 1990; Rogers et al.,
1986; Waddell and Craig, 1988). TnsA, TnsB and TnsC form a core
recombination machine that recognizes the transposon ends and
execute DNA breakage and joining, and they are speciﬁcally targeted
to attTn7 by the function of TnsD.
Previously, Luckow et al. (1993) have described a rapid and
efﬁcient method for generating a recombinant baculovirus bacmid
using Autographa californica nuclear polyhedrosis virus; this method
is based on the site-speciﬁc transposition of Tn7 in E. coli. This
baculovirus bacmid contains a mini-F replicon, a kanamycin-resis-
tance marker, and a segment of DNA carrying the LacZα gene with a
mini-attTn7, which is the attachment site for Tn7. Because the foreign
gene that is inserted into the mini-attTn7 on the bacmid disrupts the
expression of the LacZα peptide, colonies containing the recombinant
bacmid are white when grown on medium containing X-Gal. This
system has been developed into the commercially available AcNPV
Bac-to-Bac™ Baculovirus Expression System (Invitrogen). It has also
been applied to a herpesvirus, mouse cytomegalovirus and this
technology should facilitate detailedmutagenic studies of herpesvirus
genes and cis elements (Hahn et al., 2003).
In this report, we adapted this use of site-speciﬁc transposition by
Tn7 to introduce a gene expression cassette into the vOka–BAC
genome. Once a selectable marker (LacZα gene with a mini-attTn7) is
inserted into a speciﬁc site into the vOka–BAC genome with
homologous recombination using RecA, the Tn7-mediated site-
speciﬁc transposition can be done easily to rapidly introduce genes
into the vOka–BAC genome. Finally, here we have succeeded in
making a recombinant vOka expressing MuV–F gene by using this
system. This systemmay be clinically applicable to the construction of
a live polyvalent vaccine that is based on the current varicella vaccine.
Results
Construction of a vOka–BAC–Tn and insertion of a foreign gene
expression cassette
The Tn7 attachment sequence, LacZα–mini-attTn7, was inserted
into the intergenic region between ORF12 and ORF13 of the vOka–BAC
genome by RecA-mediated recombination to generate vOka–BAC–Tn
(Figs. 1A–C), as described in Materials and methods. The insertion of
the LacZα–mini-attTn7 sequence into the BAC genomewas conﬁrmed
by blue–white selection, PCR and Southern blotting.
The MuV–F donor plasmid, pFASTBac–MuV–F (Fig. 1D) was
introduced into E. coli DH10B harboring the vOka–BAC–Tn genome
and the helper plasmid, pMON7124, which expresses the Tn7 proteins
necessary for the transposition of mini-Tn7. The insertion of theMuV–
F expression cassette into the mini-attTn7 attachment site on the
vOka–BAC–Tn disrupted the expression of the LacZα peptide.
Therefore, the E. coli colonies containing the vOka–BAC–F were
distinguished by blue–white selection. The transposition of the MuV–
F expression cassette into the vOka–BAC genome was conﬁrmed by
PCR (data not shown). The completed schematic ﬂow of the
construction of the vOka–BAC–F genome is shown (Fig. 1E).
The insertion of LacZα–mini-attTn7 and MuV–F at the correct site
of the vOka–BAC genomewas veriﬁed by restriction enzyme digestion
and Southern blot analyses using BamHI-digested BAC genome
probed with either ORF12 or MuV–F gene (Fig. 2B). The 7.8 kb
fragment of vOka–BAC genome disappeared in the vOka–BAC–Tn and
vOka–BAC–F genome by the insertion of LacZα–mini-attTn7 (Figs. 2B
and C). In vOka–BAC–Tn and vOka–BAC–F genome, the 3.3 kbfragment was detected by an ORF12 probe (Fig. 2C. lanes 2, 3). The
transposedMuV–F genewas detected as a 2.9 kb fragment withMuV–
F probe (Fig. 2D lane 3). These results indicate that these fragments
were successfully inserted into the vOka–BAC genome.Reconstitution of infectious virus from the vOka–F–BAC DNA
To examine whether infectious viruses could be reconstituted
from the vOka–F–BAC DNA, MeWo cells were transfected with vOka–
F–BAC using Lipofectamine 2000 (Invitrogen). Five days after the
transfection, typical cytopathic effects along with green ﬂuorescence,
were observed by ﬂuorescence microscopy, indicating that vOka–F–
BAC had been reconstituted as an infectious recombinant virus.
Because herpesviruses containing the additional BAC sequence
might undergo mutations caused by the insertion of long non-VZV
sequences, the BAC sequence, including the gpt and gfp genes, was
excised from the rvOka–F–BAC genome, using the Cre–loxP system
(Fig. 1F), as described previously (Somboonthum et al., 2007), to
generate the recombinant virus, rvOka–F. Correct excision of the BAC
sequence from the recombinant virus was conﬁrmed by sequencing
Fig. 2. Restriction enzyme digestion and Southern blot analyses. (A) Schematic diagram
of the inserts at the ORF12–13 loci. Location of BamHI sites are indicated as arrowheads.
The size of ORF12 fragment by BamHI digestion was indicated at the right. The locations
of probes were indicated at below. (B–D) vOka–BAC, vOka–BAC–Tn and vOka–BAC–F
were digested with BamHI and separated on 0.5% agarose gel. Molecular size markers
are shown at the left. Southern blot analysis of BamHI-digested vOka–BAC (lanes 1),
vOka–BAC–Tn (lanes 2) and vOka–BAC–F (lanes 3) were performed. Probes used were
indicated.
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further experiments.
The expression of a foreign gene from recombinant virus
To determine the expression of the MuV–F protein, Western
blotting analysis was performed (Figs. 3A and B). Recombinant vOka-
infected MeWo cell lysates and MuV-infected Vero cell lysates were
separated by SDS-PAGE and analyzed by Western blotting with anti-
VZV glycoprotein B (gB) or anti-MuV–F polyclonal antibody. As shown
in Fig. 3B, VZV–gB was detected in lysates from cells infected with
both the control rvOka (Fig. 3B lane 2) and rvOka–F (Fig. 3B lane 3).
On Western blots of rvOka–F-infected cell lysates, the anti-MuV–F
antiserum speciﬁcally reactedwith 60-kDa and 15-kDa bands (Fig. 3A,
lane 3). Both bands were also detected in MuV-infected Vero cell
lysates (Fig. 3A lane 5).MuV–F is ﬁrst translated as a 70-kDa F0 protein, which is cleaved
to produce themature protein (vonMessling et al., 2004). Because the
anti-MuV–F polyclonal antibody reactedwith the C-terminal region of
the MuV–F protein, it could detect the 60-kDa and 15-kDa bands,
which are the predicted sizes of MuV–F1 and F1b, respectively. The
detection of the 15-kDa species indicated that the foreign antigen was
processed into its natural, mature form in the rvOka–F-infected cells.
We also conﬁrmed the expression of the MuV–F protein by
immunoﬂuorescence (Fig. 3C). As shown in Fig. 3C, MuV–F protein
was detected in VZV–gB-positive cells, indicating that MuV–F protein
was expressed in rvOka–F-infected cells, as expected. However, MuV–
F did not co-localize with VZV–gB within the cells. These results
indicate that the MuV–F protein was expressed and maturated
normally in the rvOka–F infected cells. The localization of MuV–F
protein in rvOka–F infected cells was the same as that of MuV-infected
Vero cells (Fig. 3C).
Growth of the recombinant virus
To compare the growth between rvOka and rvOka–F, we compared
their plaque sizes and growth curves using MRC-5 cells. As shown
in Fig. 4, plaque size (Fig. 4A) and growth curve (Fig. 4B) observed
with rvOka–F infection were similar to those observed with rvOka,
indicating that the normal growth characteristics of rvOka–F were
retained.
Immunization of guinea pigs with rvOka–F induces neutralizing
antibodies against VZV, but not MuV infection
All the guinea pigs inoculated with rvOka–F-infected cells, showed
antibody responses against both VZV (1:3200±924) and MuV
(1:1066±462 ), but none of those inoculated with the control did.
Neutralizing anti-VZV and anti-MuV antibody titers were also de-
termined by a plaque reduction assay. The serum obtained from all
the guinea pigs inoculated with rvOka–F-infected cells contained
neutralizing antibodies against VZV (Table 1), but not MuV (Table 2).
Discussion
In this report, we succeeded in constructing a rapid and handy VZV
recombination system that utilized the Tn7 transposon to integrate
gene(s) of interest into the vOka–BAC genome. The site-speciﬁc
insertion of the foreign gene expression cassette was straightforward,
and the selection of colonies bearing the recombinant BAC was easy,
via the LacZα-based blue/white selection. This system permits the
rapid construction of a recombinant vOka genome that harbors
foreign gene(s) and the reconstitution of the infectious, recombinant
virus from the genome.
The vOka–BAC genome has several advantages as a candidate for a
live viral vector. First is its long history as a safe and efﬁcient live
vaccine (Chaves et al., 2008; Galea et al., 2008). vOka is the only live
attenuated vaccine permitted for preventing VZV infection, and the
only live DNA vaccine that is acceptable for use in immunocompro-
mised individuals (Gershon et al., 1984; Kamiya et al., 1984).
Next, the vOka–BAC system is an efﬁcient method for generating
the recombinant vector in E. coli. Furthermore, the use of the
transposon system, established here, makes the insertion of a foreign
gene into vOka–BAC genome quick and easy. Thus, the vOka–BAC–
transposon system may be useful as a tool for the construction of live
varicella vaccines that also express speciﬁc genes of interest.
Finally, unlike other recombinant vaccines, a live recombinant
vaccine has the potential to induce both humoral and cell-mediated
immunity. Varicella vaccine induces both immunities, including
delayed-type hypersensitivity. We showed here that the foreign
antigen harbored by rvOka–F was expressed in rvOka–F-infected cells
and posttranslationally modiﬁed as in a natural MuV infection. Their
Fig. 3. The expression of MuV–F protein in rvOka–F infected cells. (A) MeWo cells were mock infected (lane 1; mock) or infected with rvOka (lane 2) or rvOka–F (lane 3) by cell-to-
cell spread. Vero cells weremock infected (lane 4) or infected withMuV strain Urabe (lane 5). Samples were separated by 13% SDS-PAGE and analyzed byWestern blotting with anti-
MuV–F polyclonal antibody. (B) MeWo cells were mock infected or infected with rvOka or rvOka–F by cell-to-cell spread. Samples were separated by 8% SDS-PAGE and analyzed by
Western blotting with anti-VZV–gB polyclonal antibody. (C) MeWo cells infectedwith cell-free rvOka (i) or rvOka–F (ii)wereﬁxed at 72 hpi and analyzed by confocalmicroscopy. Cells
weredouble-labeledwithMuV–F polyclonal antibody andVZV–gBmonoclonal antibody. Vero cells infectedwithMuV (iii)were ﬁxed at 24 hpi and analyzedby confocalmicroscopy. Cells
were labeled with MuV–F polyclonal antibody. Scale bar: 30 µm.
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humoral immunity. Expression of foreign antigen in the context
of the major histcompatibility complex antigen would result in
enhanced induction of cytotoxic T lymphocytes. Therefore, we expect
that our recombinant vOka vaccine will be able to induce cell-
mediated immunity aswell as humoral immunity also against foreign
protein(s).
However, the expression of foreign gene encoded in vOka–BAC
genome may affect the cell tropism and/or pathogenesis of therecombinant viruses. Especially if the foreign proteins are expressed
on the viral envelope, the tropismmay be changed. Thus, the insertion
of foreign genes into vOka which affect cell tropism and viral path-
ogenesis might be excluded in future vaccine candidates. Therefore,
the development of the polyvalent vaccine based on VZV should be
done carefully considering these points. If the vaccine is safe, the
reactivation of VZV would be advantageous because it could induce
the immunity against foreign proteins as well as VZV-encoded pro-
teins. In addition, to consider with the attenuated property of vOka,
Fig. 4. Growth of the recombinant virus. (A) Plaque sizes of rvOka or rvOka–F. MRC-5
cells infected with the indicated virus were cultured for 2 weeks, ﬁxed, and stained
with 1% crystal violet. The areas of the plaques were calculated with NIH-image. (B)
Infectious center assay of rvOka and rvOka–F. MRC-5 cells in 35-mm dishes were
infected independently with similar titers of the indicated cell-free viruses, and then
the cells were washed and trypsinized on days 0 to 5 pi. The trypsin-treated, infected
cells were diluted and transferred onto a monolayer of MRC-5 cells, and the number of
infected cells was assessed by counting the number of VZV plaques appearing after
7 days. The result shown is representative of three independent experiments.
Table 2
Neutralizing antibody titers for mumps virus in guinea pigs immunized three times
with rvOka–F.
Immunization Neutralizing antibody titers⁎
rvOka b10 b10 b10
rvOka–F b10 b10 b10
Mock control b10 b10 b10
Two independent experiments in triplicate were performed and three guinea pigs were
used in one experiment.
One of two experiments is shown.
⁎ Neutralizing antibody titer was deﬁned as the reciprocal of the highest serum
dilution that reduced the number of plaques by 50%.
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appear to be safe as well as original vOka. However, since the
molecular mechanism of attenuation remains unknown, further study
will be required to elucidate the mechanism of the vaccine
attenuation. In the case of the recombinant virus used here, the
commercially available antiviral drugs are able to be used effectively
to control the infection of the recombinant virus, because TK gene of
VZV remains in the genome.
The HN and F proteins are presented on the surface of mumps virus
particles. Anti-F protein antibody contained in sera from patients and
vaccinees contributes to the defense against MuV through activation
of complement (Hishiyama et al., 1988; Sakata et al., 1984). Therefore
the F protein was also thought to be a possible target in the host
immune system. Here the MuV–F gene was successfully introducedTable 1
Neutralizing antibody titers for VZV in guinea pigs immunized three times with rvOka–
F.
Immunization Neutralizing antibody titers⁎ Mean
rvOka–F 128 64 128 106.7
Mock control b8 b8 b8
Two independent experiments were performed and three guinea pigs were used in one
experiment.
One of two experiments is shown.
⁎ Neutralizing antibody titer was deﬁned as the reciprocal of the highest serum
dilution that reduced the number of plaques by 90%.into rvOka genome and the proteinwas expressed in rvOka–F infected
cells in a similar manner to that seen in MuV-infected cells. However,
the rvOka harboring F gene-immunized guinea pigs did not induce the
production of neutralizing antibody against MuV, although it induced
against VZV infection. The co-expression of both HN- and F proteins at
the same cells might be required for the induction of the protective
immunity against F protein. The construction of rvOka expressing
both HN and F genes may be needed to compare the protective effect
with that of rvOka expressing HN gene alone.
Previous work (Houard et al., 1995) has shown that the recom-
binant vaccinia virus expressing F protein was able to induce neu-
tralizing antibody in hamsters. The discrepancy found between this
and ours, may be due to difference of animal model used or structure
of F protein expressed. Further studies will be needed for the vaccine
application of the recombinant virus.
Materials and methods
Cells and viruses
MRC-5 cells were cultured in modiﬁed minimum essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS). MeWo cells
and Vero cells were cultured in Dulbecco's modiﬁed Eagle's medium
supplemented with 8% FBS. A recombinant vOka–BAC clone (Yoshii
et al., 2007), was used as the backbone for the recombination. rvOka
and rvOka–F were propagated in MRC-5 cells. VZV-infected cells were
cultured in DMEM supplemented with 3% FBS. The MuV Urabe strain
was propagated in Vero cells.
Antibodies
An anti-MuV–F rabbit polyclonal antibody was raised against an
MuV–F peptide, NTISSSVDDLIRY, corresponding to the 13 carboxy-
terminal residues. The anti-VZV–gB polyclonal (Sadaoka et al., 2007)
and monoclonal (Okuno et al., 1983) antibodies were described
previously. Secondary antibodies conjugated to ﬂuorophores, anti-
mouse IgG–Alexa Fluor 594 and anti-rabbit IgG–Alexa Fluor 488
(Invitrogen, Carlsbad, CA), were used for immunoﬂuorescence assays.
HRP-conjugated anti-rabbit IgG (GE Healthcare Bio-Science, Piscat-
away, NJ) was used for Western blotting.
Plasmids
The gentamicin-resistance gene and the polyhedrin-promoter
region of the pFASTBac1 plasmid (Invitrogen) were replaced with
the CMV promoter to generate the pFASTBacCMV plasmid. The CMV
promoter sequence was ampliﬁed by PCR from pcDNA3.1(+) and
inserted into the SacII and BamHI sites of the pFASTBac1 plasmid. The
MuV–F cDNA was inserted into the multi-cloning site of pFAST-
BacCMV to generate the pFASTBacCMV–MuV–F plasmid. The MuV–F
cDNA was obtained as described previously (Somboonthum et al.,
2007).
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pairs; bp) 16,689–18,352 was ampliﬁed using a primer pair that
introduced Xho I and BamH I sites (underlined) at the 5′ and 3′ ends,
respectively: 5′-TATCTCGAGAGGTACCGGTGACTTCAGAG-3′ (12TnFw)
and 5′-CGAGGATCCAATCAACCAATCAGACCT-3′ (12TnRv). The VZV ORF
13DNA fragment frombp18,390 to 19,618was ampliﬁed using a primer
pair that introduced BamH I and Xho I sites (underlined) at the 5′ and
3′ ends, respectively: 5′-GAGGATCCGTACCCACAATATCAAGTGGT-3′
(13TnFw) and 5′-GACTCGAGCCTATTCGTGTCATCTAGATGG-3′
(13TnRv). The resulting fragments were digested with BamH I and
Xho I and then ligated into theXho I site of pBluescript SK(−) to generate
pB1213Tn. pB1213Tn was digested with Xho I to release the 1213Tn
fragment, which was then cloned into the Sal I site of pKO5M which
encodes zeocin resistant gene (a kind gift from Dr. Y. Kawaguchi)
(Tanaka et al., 2003), from which the BamH I site had been previously
eliminated, to generate pKO5M-1213Tn. The LacZα–mini-attTn7 region,
which contains the attachment site for Tn7, of bMON14272 (Invitrogen)
was ampliﬁed using the following primer pair: 5′-GAAGATCTGAACC-
AATACGCAAACCGCCTCTCCCCGCGCG-3′ (lacZα-PR1) and 5′-GAGAGTC-
TGAAGCGCGTAACCACCACACCCGCCGCGC-3′ (lacZα-PR2). The resulting
fragmentwasdigestedwith Bgl II and then cloned into theBamH I site of
pKO5M-1213Tn to produce pKO5M-Tn (Fig. 1).
RecA-mediated recombination to generate the vOka–BAC–Tn
The insertion of the LacZα–mini-attTn7 cassette to produce vOka–
BAC–Tn was performed using RecA-mediated recombination, essen-
tially as described previously (Somboonthum et al., 2007). In brief,
E. coli DH10B electrocompetent cells harboring circular vOka–BAC
DNA genome, which encodes chloramphenicol resistant gene, were
co-transformed with the targeting vector, pKO5M-Tn and pDF25(Tet)
which encodes RecA gene and tetracycline resistant gene (a kind gift
fromDr. J. Heath) (Lalioti and Heath, 2001) by electroporation, using a
Gene Pulser II (Bio-Rad, Hercules, CA). The surviving co-integrant
colonies, selected by their resistance to chloramphenicol and zeocin
and a Lac+ phenotype on an LB plate containing X-Gal and IPTG, were
made electrocompetent and transformed with pDF25(Tet). The desi-
rable E. coli DH10B colonies containing the correct survival recom-
bination were then selected upon by the following criteria: resistance
to chloramphenicol, sensitivity to zeocin, and a Lac+ phenotype on LB
containing X-Gal and IPTG. The correct integration of the insert was
conﬁrmed by restriction enzyme digestion.
E. coli DH10Bharboring the vOka–BAC–Tngenomewas transformed
with pFASTBacCMV–MuV–F and the helper plasmid expressing the
transposase, TnsABCD, pMON7124 (Invitrogen). The pMON7124 plas-
mid was isolated from DH10Bac cells (Invitrogen). The transformed E.
coli was cultured on LB containing X-gal and IPTG for blue/white
selection.White colonieswere analyzed by PCR to verify the insertion of
the MuV–F expression cassette.
Southern blotting
vOka–BAC DNA, vOka–BAC–Tn DNA, or vOka–BAC–F DNA was
digestedwith BamHI and separated by electrophoresis in 0.5% agarose
gel. After transfer to Hybond-N+ nylon membranes (GE Healthcare
Biosciences), the blots were hybridized with the appropriate DNA
probe labeled with horseradish peroxidase using enhanced chemilu-
minescence direct nucleic acid labeling and detection systems (GE
Healthcare Biosciences) according to the manufacturer's instructions.
Reconstitution of infectious virus from vOka–BAC DNA
Reconstitution of the recombinant virus, named rvOka–F, was per-
formed, with modiﬁcations, as described previously (Nagaike et al.,
2004). Brieﬂy, the recombinant bacmid was introduced into MeWo
cells with Lipofectamine 2000 (Invitrogen). To remove the BACsequence, which was ﬂanked by loxP sequences and contained the
gene for guanine phosphoribosyl transferase gene (gpt) and green
ﬂuorescence protein gene (gfp), MRC-5 cells were ﬁrst infected with a
recombinant adenovirus, AxCANCre (a kind gift from Dr. Y. Kawaguchi)
(Tanaka et al., 2003), that expresses Cre recombinase. Twenty-four
hours later, the cells were super-infected with the recombinant virus
and cultured until plaques without GFP appeared. The GFP-negative
plaques were isolated using glass isolation cups and transferred onto
newly prepared MRC-5 cells. The successful excision of the BAC
sequencewas veriﬁed by PCR and the sequencing of cell-free viral DNA.
Immunoﬂuorescence assays
Immunoﬂuorescence assays were performed, with modiﬁcations,
as described previously (Koshizuka et al., 2008). Brieﬂy, rvOka- or
rvOka–F-infected MeWo cells, or MuV-infected Vero cells were ﬁxed
with cold acetone–methanol, and reacted with the anti-gB monoclo-
nal and anti-MuV–F polyclonal antibodies. After the secondary
antibody reaction, the cells were rinsed with PBS, mounted on glass
slides, and observed with the Leica confocal microscope system.
Growth analysis of rvOka–F
MRC-5 cells were infected with approximately 25 pfu of cell-free
rvOka or rvOka–F virus, and incubated for 2 weeks at 37 °C followed
by staining with 1% crystal violet/70% ethanol. The plaque sizes were
calculated using NIH-image (NIH, USA). Infectious center assay was
performed as described previously (Somboonthum et al., 2007).
VZV inoculation to animals
VZV inoculation to guinea pigs was performed as described
previously with slight modiﬁcation (Somboonthum et al., 2007).
The VZV-infected MRC-5 cells (3×106 cells) suspended in PBS were
administered to animals subcutaneously. The uninfected MRC-5 cells
(5×106 cells) in PBS were used as negative control. Three weeks after
the inoculation, the same antigens were immunized to the animals
again. Blood was collected by cardiac puncture 7 days after the second
inoculation. Sera were inactivated at 56 °C for 30 min for the
serological and Neutralization tests.
Plaque reduction neutralization assay for VZV and MuV
The neutralizing anti-VZV antibody titers were also determined by
a plaque reduction assay. Stock virus solution (0.1 mL containing
100 pfu of vOka strain) was mixed with 0.1 mL of serially diluted
serum at the appropriate dilution (rvOka–F immunized serum; 1:16
to 1:512, or mock immunized serum; 1:8 to 1:256) and 0.1 mL of fresh
guinea pig serum as a source of complement, and the mixtures were
incubated at 37 °C for 30 min. Next, MeWo cells were inoculated with
0.2 mL of each mixture in six-well plates, and incubated at 37 °C for
1 h to allow adsorption. The inoculum was then removed, and the
cells were washed and cultured for 5 days, followed by staining with
1% crystal violet/70% ethanol. The stained cells were then washed,
and the plaques were counted. The neutralizing antibody titer was
determined as the highest dilution of serum capable of reducing the
number of virus plaques by 90% or more, compared with the control
values, and expressed as the reciprocal of the dilution. Anti-MuV
neutralizing antibody titers were determined by a plaque reduction
assay as described previously (Somboonthum et al., 2007).
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